With respect to BMT, since the time the model was devised, it has become clear that use of both GLP-1 RA and SGLT2 inhibitors may confer additional benefits for patients with T2DM in terms of reduction of adverse cardiovascular and renal outcomes [37,38]—future analyses would factor this in. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.